MediWound Secures $140M Government Funding, Targets $831M EscharEx Peak Sales
MediWound reported $54 million cash, no debt and a $30 million raise last quarter, projecting NexoBrid revenue growth through 2028 and potential EscharEx peak sales of ~$831 million if Phase III succeeds. The company secured $140 million in non-dilutive U.S. government funding and expects a BARDA agreement in Q1 2026.
1. Commercial and Financial Highlights
MediWound holds $54 million in cash with no debt and completed a $30 million financing last quarter. NexoBrid is FDA/EMA approved, commercialized in over 40 countries including the U.S., Europe and Japan, and is driving current revenue and profitability.
2. EscharEx Phase III Development
EscharEx, using the same enzyme as NexoBrid at half concentration, is in a 216-patient Phase III venous leg ulcer trial across ~40 U.S. and European sites. The study’s co-primary endpoints are complete debridement and wound closure facilitation, with an interim readout expected in late 2026.
3. Manufacturing Expansion and Regulatory Timeline
The new manufacturing facility is operational and producing NexoBrid inventory, pending three- and six-month stability data. MediWound aims to request EMA inspection around mid-2026, followed by FDA review, to alleviate current supply constraints and support global demand.
4. Government Funding and BARDA Agreement
The U.S. government has provided $140 million in non-dilutive funding for burn treatment and battlefield applications. A BARDA contract with Vericel is anticipated in Q1 2026 to cover stockpiling, a room-temperature stable formulation and blast-injury development.